30
Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor of Medicine Chief of Cardiology Associate Chief Cardiology University California Irvine Orange, California

Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

  • Upload
    others

  • View
    4

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Hemodynamics: essentials for future

TAVR and mitral valve disease

Morton J. Kern, MD

Professor of Medicine Chief of Cardiology

Associate Chief Cardiology University California Irvine

Orange, California

Page 2: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Disclosure:

Morton J. Kern, MD

Within the past 12 months, the presenter or their

spouse/partner have had a financial interest/arrangement

or affiliation with the organization listed below.

Company Name Relationship

St. Jude Medical Inc. Speakers’ Bureau

Volcano Therapeutics Speakers’ Bureau

Merrit Medical Inc. Consultant

Opsens Consultant

Page 3: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Etiology of Aortic Stenosis From the Euro Heart Survey

Goldbarg, S. H. et al. J Am Coll Cardiol 2007;50:1205-1213

Page 4: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

J Am Coll Cardiol. 2012;60(3):169-180.

Pathophysiology of AS

Page 5: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Tri/MV valves open

Pa/Ao valves

are closed

Pa/Ao

valves open

Tri/MV valves close

Pa/Ao

valves close

Tri/MV valves open systole

=Valve action

Page 6: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Mechanism of AS: LV-Ao Gradient

Consequences of LV-Ao

Gradient:

1. late peaking Systolic

murmur

2. Single A2

3. Slow pulse upstroke

Page 7: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

BAMC Case #3117:

Patient: 61 yo male

Dx: 3V CAD

filter: 50 Hz/ sample 250 Hz Pre Contrast

Normal LV and Aortic Pressure Fluid-filled system

micromanometer transducers Fluid filled, FA sheath

Page 8: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

P-P grad Mean Grad

Peak instantaneous vs P-P

Unshifted=larger Grad

LV

Fusberg and Feldman T, Cath and CV Int 53:553;2001

Hemodynamic Technique

Page 9: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Techniques for Aortic Valve

Gradient Measurement

• Single Catheter LV-Ao pullback

• LV and Femoral Sheath

• LV and Long aortic sheath

• Bilateral femoral access

• Double-lumen pigtail catheter

• Transeptal LV access with ascending Ao

• Pressure Guidewire with ascending Ao

• Multi-transducer micromanometer catheters

Fusberg and Feldman T, Cath and CV Int 53:553;2001

Page 10: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Calculating Aortic Valve Area

• AVA: Gorlin equation

• AVA: Hakke formula (“poor man’s Gorlin”)

– Assumes HR*SEP*44.3 = 1000 in most patients

– Valid for HR ~65-100

AVA = cardiac output (L/min)/√Peak-Peak Pressures

Page 11: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Grading Severity of Aortic Stenosis

AVA AVA Index Aortic Stenosis (cm2) (cm2/m2) Mild >1.5 >0.9 Moderate 1.1-1.5 >0.6-0.9 Severe <0.8-1.0 <0.4-0.6

Page 12: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor
Page 13: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor
Page 14: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Hemodynamic Differentiation of LVOT Obstruction

AS HOCM

3 Differentiating features a. Aortic upstroke b. Pulse pressure c. Contour –spike/dome

Page 15: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Low Gradient, Low EF AS?

LVEF 25%

P-P gradient 30mmHg

CO = 3.2l/m Fick

AVA = 0.7cm2

Page 16: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Base 10 Dob+Pace 80 20 Dob + Pace 95

Dobutamine challenge for LG AS

P-P = 50mmHg CO = 4.2l/m

AVA = 0.6cm2

Page 17: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Grayburn, P. A. Circulation 2006;113:604-606

What should you do with Symptomatic AS patient, low gradient, low flow? The Dobutamine Challenge

AVA = 0.7cm2

AVA = 1.0cm2

AVA = 1.5cm2

Fixed area

Page 18: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Chiam, P. T.L. et al. J Am Coll Cardiol Intv 2008;1:341-350

Edwards-Sapien PHV CoreValve PHV

Page 19: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor
Page 20: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor
Page 21: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Pre- Post 26mm Sapien Edwards

Anachrotic shoulder, dichrotic notch

Diastolic dysfunction? Delayed upslope

Page 22: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

AS+AI

Page 23: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor
Page 24: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Normal LA and LV

diastolic pressures LA-LV Diastolic Gradient

Page 25: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

PCW does not always equal LA

Page 26: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Hemodynamics and Doppler Echo findings before MVBP

Page 27: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor
Page 28: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Hemodynamic and Doppler Echo findings after MVBP

Page 29: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor
Page 30: Hemodynamics: essentials for future TAVR and mitral valve disease · 2020-01-31 · Hemodynamics: essentials for future TAVR and mitral valve disease Morton J. Kern, MD Professor

Hemodynamics for Structrual Heart Disease

Low Gradient AS

Complications of AVP – AI

AS vs. HOCM

Mitral Regurgitation after MVP for MS

Diastolic CHF – constrictive v Restrictive

Tamponade

For your own review consider Intracardiac Shunts